2 responses to “Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors: New drug class in the treatment of Heart Failure with Reduced Ejection Fraction — DAPA-HF and EMPEROR-Reduced trials”

  1. The average age of study participants was in the 60s. Were outcomes measured for frail, elderly patients, and did they benefit? Were patients with comorbidities such as CKD included? Also, what was the TTB? (time to benefit). Thanks.

  2. I echo Judith’s questions. Also, what are the implications for increased hypotension risk in frail elderly who are are already on medication for heart failure management?

Leave a Reply